Non-drug industry funded research

Editorial

Paolo Bruzzi. BMJ. 2008.

. 2008 Jan 5;336(7634):1-2.

doi: 10.1136/bmj.39416.559942.BE. Epub 2007 Dec 6.

Abstract

Poor access to drugs leaves important clinical questions unanswered

Competing interests: None declared.

1. Berendt L, Håkansson C, Bach KF, Dalhoff K, Andreasen PB, Petersen LG, et al. Effect of European Clinical Trials Directive on academic drug trials in Denmark: retrospective study of applications to the Danish Medicines Agency 1993-2006. BMJ 2008;336:33. - PMC - PubMed
1. Agenzia Italiana del Farmaco. La sperimentazione clinica dei medicinali in Italia—6° Rapporto Nazionale. 2007. http://oss-sper-clin.agenziafarmaco.it
1. Baum M, Buzdar AU, Cuzik J, Forbes J, Houghton JH, Klijn JG, et al; ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9. Erratum, Lancet 2002;360:1520. - PubMed
1. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92. - PubMed
1. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802. - PubMed